From basic research to therapy

BMA
Award 2016
'Highly Commended'

Retinal Pharmacotherapeutics

Editors:

Quan Dong Nguyen
Eduardo B. Rodrigues
Michel Eid Farah
William F. Mieler
Diana V. Do

The use of pharmacotherapeutics in the management of retinal diseases is rapidly evolving, and a favorable therapy for the patient. Today anti-VEGF agents are used for a range of indications from inflammation-related choroidal neovascularization to macular edema secondary to retinal vein occlusion or diabetic retinopathy. Beyond VEGF, there is an array of target areas under investigation – not only for vascular pathologies such as age-related macular degeneration and diabetic eye disease, but also for degenerative, infectious and inflammatory retinal conditions. This publication discusses many aspects from basic research on the retina, to animal models for retinal drug delivery, retinal diseases that are amenable to pharmacotherapy and also drugs and mechanisms in retinal diseases. Anyone concerned with the management of retinal diseases – the general ophthalmologist and the retina specialist alike – will find this book indispensable reading.

'Highly Commended' in the category
'Internal Medicine' at the 2016
BMA Medical Book Competition

www.karger.com/deoph

KARGER

Contents

Foreword: [Miller, J.W.](#)

Basic Sciences in the Retina

Evolving Knowledge in Pharmacologic Treatments of Age-Related Macular Degeneration: [Soubrane Daguet, G.](#); [Risard-Gasiorowski, S.](#); [Massamba, N.](#)

Retinal Anatomy and Pathology: [Gupta, M.P.](#); [Herzlich, A.A.](#); [Sauer, T.](#); [Chan, C.-C.](#)

Retinal Biochemistry, Physiology and Cell Biology: [Smith, R.L.](#); [Sivaprasad, S.](#); [Chong, V.](#)

Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors: [Rubio, R.G.](#); [Adamis, A.P.](#)

Ocular Immunity and Inflammation: [Albini, T.A.](#); [Davis, J.L.](#)

Complement Activation and Inhibition in Retinal Diseases: [Kleinman, M.E.](#); [Ambati, J.](#)

Genetics in Retinal Diseases: [Riaz, M.](#); [Baird, P.N.](#)

Animal Models and Routes for Retinal Drug Delivery:

Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections: [Meyer, C.H.](#); [Krohne, T.U.](#); [Charbel Issa, P.](#); [Liu, Z.](#); [Holz, F.G.](#)

Routes for Drug Delivery to the Retina: Topical, Transscleral, Suprachoroidal and Intravitreal Gas Phase Delivery: [Yamada, N.](#); [Olsen, T.W.](#)

Routes for Drug Delivery: Sustained-Release Devices: [Yun, S.](#); [Huang, J.J.](#)

Microspheres and Nanotechnology for Drug Delivery: [Jóhannesson, G.](#); [Stefánsson, E.](#); [Loftsson, T.](#)

Thermo-Responsive Hydrogels for Ocular Drug Delivery: [Kang-Mieler, J.J.](#); [Mieler, W.F.](#)

Retinal Diseases Amenable to Pharmacotherapy

Nonneovascular Age-Related Macular Degeneration: [Michels, S.](#); [Garhöfer, G.](#)

Neovascular Age-Related Macular Degeneration: [Shao, J.](#); [Choudhary, M.M.](#); [Schachar, A.P.](#)

Diabetic Retinopathy and Diabetic Macular Edema: [Cohen, S.R.](#); [Gardner, T.W.](#)

Retinal Vein Occlusion: [Sawada, O.](#); [Ohji, S.](#)

Retinal Detachment and Proliferative Vitreoretinopathy: [Kwon, O.W.](#); [Song, J.H.](#); [Roh, M.I.](#)

Posterior Uveitis: [Uy, H.S.](#); [Yu-Keh, E.](#); [Chan, P.S.](#)

Choroidal Neovascularization Secondary to Myopia, Infection, and Inflammation: [Weber, M.L.](#); [Heier, J.S.](#)

Ocular Infection: Endophthalmitis: [Schwartz, S.G.](#); [Flynn, H.W. Jr.](#); [Das, T.](#); [Mieler, W.F.](#)

Treatment for Macular Telangiectasia Type 2: [Charbel Issa, P.](#); [Kupitz, E.H.](#); [Heeren, T.F.C.](#); [Holz, F.G.](#)

Neovascular Glaucoma: [Havens, S.J.](#); [Gulati, V.](#)

Retinal Hereditary and Degenerative/Dystrophic Diseases (Non-Age-Related Macular Degeneration): [Battaglia Parodi, M.](#); [La Spina, C.](#); [Corradetti, G.](#); [Berchicci, L.](#); [Petruzzi, G.](#); [Bandello, F.](#)

Drugs and Mechanisms in Retinal Diseases

Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal Diseases: [Rodrigues, E.B.](#); [Farah, M.E.](#); [Mantovani Bottós, J.](#); [Bom Aggio, F.](#)

Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone: [Cáceres-del-Carpio, J.](#); [Donato Costa, R.](#); [Haider, A.](#); [Narayanan, R.](#); [Kuppermann, B.D.](#)

Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab: [Klein, A.](#); [Loewenstein, A.](#)

Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab: [Smith, A.G.](#); [Kaiser, P.K.](#)

Biologic Therapies: Anti-Tumor Necrosis Factor- α , Anti-Interleukins, Rituximab and Others: [Bhatt, N.](#); [Tucker, W.](#); [Sen, H.N.](#); [Nussenblatt, R.B.](#)

Immunomodulatory Therapy in Uveitis: [Tomkins-Netzer, O.](#); [Talat, L.](#); [Ismetova, F.](#); [Samy, A.](#); [Lightman, S.](#)

Sirolimus for Retinal and Uveitic Diseases: [Agarwal, A.](#); [Rajagopalan, N.](#); [Hassan, M.](#); [Sadiq, M.A.](#); [Soliman, M.K.](#); [Afridi, R.](#); [Sepah, Y.J.](#); [Nguyen, Q.D.](#)

Fusion Proteins: Aflibercept (VEGF Trap-Eye): [Sarwar, S.](#); [Bakbak, B.](#); [Sadiq, M.A.](#); [Sepah, Y.J.](#); [Shah, S.M.](#); [Ibrahim, M.](#); [Do, D.V.](#); [Nguyen, Q.D.](#)

The Protein Kinase C Inhibitor: Ruboxistaurin: [Deissler, H.L.](#); [Lang, G.E.](#)

Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy: [Jack, L.S.](#); [Sadiq, M.A.](#); [Do, D.V.](#); [Nguyen, Q.D.](#)

Platelet-Derived Growth Factor Inhibitors: A Potential Therapeutic Approach for Ocular Neovascularization: [Sadiq, M.A.](#); [Hanout, M.](#); [Sarwar, S.](#); [Hassan, M.](#); [Agarwal, A.](#); [Sepah, Y.J.](#); [Do, D.V.](#); [Nguyen, Q.D.](#)

Ocular Gene Therapy: [Campbell, J.P.](#); [McFarland, T.J.](#); [Stout, J.T.](#)

Neuroprotection and Retinal Diseases: [Paulus, Y.M.](#); [Campbell, J.P.](#)

Photosensitizers and Photodynamic Therapy: Verteporfin: [Battaglia Parodi, M.](#); [La Spina, C.](#); [Berchicci, L.](#); [Petruzzi, G.](#); [Bandello, F.](#)

Chemotherapy for Malignant Intraocular Tumors: [Shah, C.P.](#); [Shields, C.L.](#); [Shields, J.A.](#)

Antibiotics: [Hariprasad, S.M.](#); [Mieler, W.F.](#)

Pharmacotherapy and Surgery

Enzymatic Vitrectomy and Pharmacologic Vitreodynamics: [Shah, A.R.](#); [Trese, M.T.](#)

The Use of Vital Dyes during Vitreoretinal Surgery – Chromovitrectomy: [Farah, M.E.](#); [Maia, M.](#); [Penha, F.M.](#); [Rodrigues, E.B.](#)

The Last Words

Regulatory and Economic Considerations of Retinal Drugs: [Shah, A.R.](#); [Williams, G.A.](#)

Value-Based Medicine and Pharmacoeconomics: [Brown, G.C.](#); [Brown, M.M.](#)

Future Perspectives: Agents on the Horizon: [Maya, J.R.](#); [Sadiq, M.A.](#); [Agarwal, A.](#); [Kaiser, P.K.](#); [Stoller, G.L.](#); [Sepah, Y.J.](#); [Nguyen, Q.D.](#)

Vol. 55
Developments in Ophthalmology:
Retinal Pharmacotherapeutics
Editors: **Nguyen, Q.D.** (Omaha, NE); **Rodrigues, E.B.;**
Farah, M.E. (São Paulo); **Mieler, W.F.** (Chicago, IL);
Do, D.V. (Omaha, NE)

XVI+408 p., 83 figures, 71 in color, and 33 tables, 2016
CHF 317.00 / EUR 296.00 / USD 373.00 (hard cover)
CHF 380.00 / EUR 355.00 / USD 448.00 (online)
Online version for institutional purchase
Prices subject to change, VAT not included.
EUR price for eurozone countries,
USD price for USA and Latin America only
ISBN 978-3-318-05564-1 (hard cover)
e-ISBN 978-3-318-05565-8

Orders

Orders can be placed at agencies, bookstores,
directly with the publisher, or with any Karger
distributor.

e: orders@karger.com

S. Karger AG, P. O. Box, 4009 Basel (Switzerland)
f: +41 61 306 12 34

www.karger.com/deoph

Further publications in the field

Vol. 54
Developments in Ophthalmology
Microincision Vitrectomy Surgery
Emerging Techniques and Technology
Editors: **Oh, H.** (Amagasaki); **Oshima, Y.** (Tokyo)
XII + 248 p., 145 fig., 124 in color, 10 tab., 2014
CHF 224.00 / EUR 187.00 / USD 264.00 (hard cover)
CHF 269.00 / EUR 224.00 / USD 317.00 (online)
ISBN 978-3-318-02660-3
e-ISBN 978-3-318-02661-0

Vol. 53
Developments in Ophthalmology
Cell-Based Therapy for Retinal Degenerative Diseases
Editors: **Casaroli-Marano, R.P.** (Barcelona);
Zarbin, M.A. (Newark, N.J.)
XII + 206 p., 55 figures, 41 in color, and 6 tables, 2014
CHF 198.- / EUR 185.- / USD 233.00 (hard cover)
CHF 238.- / EUR 222.- / USD 280.00 (online)
ISBN 978-3-318-02584-2
e-ISBN 978-3-318-02585-9

Find further information on these titles and back volumes in the book
series **Developments in Ophthalmology**, Series Editor: **F. Bandello**, Milan:

www.karger.com/deoph

Ophthalmologica

**Patient-oriented research in ophthalmology with special focus on
management of retina and vitreous diseases**

Editor:
S. Wolf, Bern

Associate Editors:
J. Bainbridge, London
F. Bandello, Milan
G. Coscas, Créteil
H. Heimann, Liverpool
M. La Cour, Copenhagen
A. Loewenstein, Tel Aviv
Y. Ogura, Nagoya
G. Richard, Hamburg
C. van Meurs, Rotterdam
R. Tadayoni, Paris

www.karger.com/oph

Online version for institutional purchase
Prices subject to change
EUR price for eurozone countries, USD price for USA and Latin America only

KARGER

Vol. 55 **Retinal Pharmacotherapeutics**

Vol. 54 **Microincision Vitrectomy Surgery**

Vol. 53 **Cell-Based Therapy for Retinal**

Ophthalmologica: **The European Retina Journal**

www.karger.com/deoph

Library Recommendation

Dear Librarian

I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

www.karger.com/ophthalmology

USA: S. Karger Publishers, Inc., 26 West Avon Road, P.O. Box 529, Unionville, CT 06085, Toll free: +1-800-828-5479

Germany: S. Karger GmbH, 79095 Freiburg

France: Enter & Read, Albertine Luginbuhl, 75014 Paris

Japan: Karger Japan, Inc., Tokyo 105-0012

South East Asia, China and Taiwan: Karger China, Shanghai 200001

Russian Federation: World of Periodicals, Moscow 125190

For details and further representatives and agencies see:

www.karger.com/worldwide